ABSTRACT
The severe acute respiratory syndrome coronavirus 2 pandemic has resulted in the development of various therapeutics to treat and prevent major complications related to the virus; pregnant patients are vulnerable to acquiring severe acute respiratory syndrome coronavirus 2 because of frequent contact with the healthcare setting. Despite the publication of a plethora of case series and randomized control trials of severe acute respiratory syndrome coronavirus 2 therapeutics, few have addressed treatment in the pregnant population. To date, there has been no published review of therapeutic options in the treatment of pregnant patients with severe acute respiratory syndrome coronavirus 2 infection. Here, we provide a review of available treatments for severe acute respiratory syndrome coronavirus 2, various trials with inclusion and exclusion of the pregnant patients, and potential side effects of each treatment in the pregnant patient.
Subject(s)
Antiviral Agents/pharmacology , COVID-19/therapy , Pregnancy Complications, Infectious/drug therapy , SARS-CoV-2/drug effects , Anticoagulants/pharmacology , COVID-19/diagnosis , Female , Humans , Immunization, Passive/methods , Patient Selection , Pregnancy , Pregnancy Complications, Infectious/diagnosis , COVID-19 Serotherapy , COVID-19 Drug TreatmentABSTRACT
Our hospital adopted universal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing for labor and delivery patients in April 2020. The primary aim of this study was to determine the number of subjects from April 1, 2020, to July 31, 2020, who had laboratory-confirmed SARS-CoV-2 infection, and the secondary aims were to report demographic and clinical data for subjects with and without SARS-CoV-2 infection and the time from SARS-CoV-2 test collection to result for tests administered in the hospital. A total of 898 subjects had either vaginal or cesarean deliveries with a gestational age of >20 weeks during the study period. Of this group, 746 subjects underwent SARS-CoV-2 testing, and 16 had a positive test result. Four of the 16 subjects with laboratory-confirmed SARS-CoV-2 infection had documented symptoms at the time of admission. The difference in cohort size was too large to make a meaningful statistical comparison in demographic and clinical data between those with positive vs negative SARS-CoV-2 test results. The median time from SARS-CoV-2 test collection to result decreased from 239 minutes in April 2020 to 119 minutes in July 2020. Universal SARS-CoV-2 testing revealed a 2.1% positivity rate during our study period.